Our Science
Our Story
News
Connect
Globe Newswire
August 1, 2024
Featured article
Read More
March 21, 2021
In The News
Endpoints News
A pair of Lyell founders look to shift the cell therapy paradigm — and they've got $30M to get their plan off the ground
READ MORE
DOWNLOAD
1
All
PR
Publications
November 19, 2024
Society for Immunotherapy of Cancer (SITC)
November 5, 2024
Public Relations
Outpace Bio to present new data on programmed CAR T cell candidate OPB-101 at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies into Clinical Development
With $144M Series B, Outpace Bio beats funding goal for solid tumor cell therapies
synbiobeta
AI-Driven Cell Therapy Pioneer Outpace Bio Raises $144M in Series B Funding
GeekWire
Protein design startup Outpace lands $144M to test treatments that target solid tumors
May 11, 2023
BioCentury
Keeping up with the protein designers
June 28, 2022
Biotech startups join AWS and other partners in open-source project to help design new proteins
February 21, 2022
Fred Hutch Cancer Center
Red Light, Green Light: Precise cell targeting with Co-LOCKR
October 6, 2021
Business Insider
Power players: These 12 young serial founders are building the next generation of biotech startups
May 18, 2021
Lyell spinout Outpace leverages de novo proteins to control cell and gene therapies
April 5, 2021
Forbes
Outpace Bio raises $30 Million to design next generation cell therapies
April 4, 2024
Outpace Bio Announces Multiple Presentations at the 2024 American Association of Cancer Research (AACR) Annual Meeting
October 31, 2023
Outpace Bio to present new data on tumor-restricted IL-12 designed leveraging OutSmart technology to enhance solid tumor T cell therapies at SITC 2023
May 22, 2023
Outpace Bio expands Seattle presence with cell therapy research hub & collaborations with leading experts in protein design & cancer immunotherapy
May 18, 2023
Outpace Bio to present new data on OutSmart™ IL-2/15, a CAR T cell-produced designed cytokine with tumor-localized immune cell activity, at the 2023 annual meeting of the American Society of Gene & Cell Therapy (ASGCT)
August 1, 2023
American Society for Gene & Cell Therapy (ASGCT)
OutSmart™ IL-2/15 Safely Stimulates CAR T Proliferation and Persistence in the Tumor while Limiting Regulatory T Cell Activation
OutSmart™ IL-2/15: A CAR T Cell-Produced Designed Cytokine with Tumor-Localized Immune Cell Activity
November 7, 2022
Tuning the cell-cell distance via the non-signaling extracellular spacer domain of chimeric antigen receptors is critical for optimal activity
October 11, 2022
Frontiers in Molecular Medicine
Safety switch optimization enhances antibody-mediated elimination of CAR T cells
The Outpace Press Kit is designed to help journalists research Outpace. Please contact our communications team if you need more information or to schedule an interview.